<DOC>
	<DOCNO>NCT01334047</DOCNO>
	<brief_summary>In study investigator include patient relapsed epithelial ovarian cancer . In spite increase rate complete response initial chemotherapy , patient advance ovarian cancer relapse succumb progressive disease . Immunotherapy may potential consolidation therapy . Dendritic cell vaccine well toleranted previous study , minor side effect serious adverse event registrated In study , patient receive DC-vaccine therapy response platinum treatment relapse . The investigtors include patient good clinical condition severe symptoms disease . If patient relapse vaccine treatment , discontinue study . The investigator include hTERT- survivin mRNA addition amplify cancer stem cell mRNA vaccine .</brief_summary>
	<brief_title>Trial Vaccine Therapy Recurrent Platinum Sensitive Ovarian Cancer Patients</brief_title>
	<detailed_description>Study Period : - Estimated date first patient enrol : First quarter 2011 - Anticipated recruitment period : 3 year - Estimated date last patient complete : First quarter 2017 , follow 2022 . Treatment duration : Patients receive intradermal immunization week 4 week follow monthly `` vaccine boost '' first year . Patients show immunological response continue vaccination every month second third year long vaccine available . The patient follow 5 year progression disease evaluate investigator .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm epithelial ovarian cancer . Histologic documentation original primary tumor require via pathology report . Completed first line treatment ( surgery adjuvant neoadjuvant treatment carboplatine paclitaxel ) Relapsed platinum sensitive epithelial ovarian carcinoma patient response chemotherapy recurrent disease If surgery indicate , patient surgically treat start vaccination minimum interval 28 day . Must ambulatory ECOG performance status 0 1 . Life expectancy ≥ 6 month Must 1875 year age Must lab value follow : ANC ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hb ≥ 9 g/dL ( ≥ 5.6 mmol/L ) Creatinine ≤ 140 μmol/L ( 1.6 mg/dL ) ; borderline , creatinine clearance ≥ 40 mL/min Bilirubin within upper limit normal ASAT ALAT ≤ 2.5 upper limit normal Albumin level low normal value If patient preserve fertility primary treatment , must practice adequate contraception study treatment Signed informed consent expect cooperation patient treatment follow must obtain document accord ICH/GCP , national/local regulation . Eligible otherwise curative treatment . History prior malignancy , ovarian cancer , within last 5 year , exception curatively treat basal cell carcinoma cancer situ cervix uterus . Prior surgery within past 28 day Clinical ascites metastatic pleural fluid Active infection require antibiotic therapy . Have know active central nervous system ( CNS ) leptomeningeal metastasis ( brain metastasis ) . Patients sign symptom neurological compromise appropriate radiographic imaging perform study entry rule brain metastasis . Significant cardiac medical mental illness would limit activity survival , severe congestive heart failure , unstable angina , serious cardiac arrhythmia psychosis . Pregnancy lactation Previous adverse reaction vaccine asthma , anaphylaxis serious reaction . History immunodeficiency autoimmune disease limit rheumatoid arthritis , systemic lupus erythematosus , scleroderma , polymyositisdermatomyositis , juvenile onset insulin dependent diabetes , vasculitic syndrome . Positive syphilis ( treponema pallidum ) , HIV , Hepatitis B C test Use systemic glucocorticoid . Prior anticancer treatment , include radiotherapy , chemotherapy immunotherapy and/or immunomodulating agent stop less 4 week first study treatment administration . Anti hormonal treatment , Tamoxifen , may continue first study treatment administration . Any reason , opinion investigator , patient participate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>